AlphaCentric Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

AlphaCentric Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-32,500	Closed	-$2.28M	–	219
2024 Q3	$2.28M	Buy	32,500 +16,000	+97%	+$1.34M	1.7%	11
2024 Q2	$1.36M	Buy	16,500 +1,000	+6%	+$83.3K	1%	31
2024 Q1	$1.35M	Buy	15,500 +1,500	+11%	+$134K	0.82%	48
2023 Q4	$1.35M	Sell	14,000 -2,500	-15%	-$221K	0.91%	40
2023 Q3	$1.46M	Hold	16,500	–	–	0.83%	39
2023 Q2	$1.43M	Buy	16,500 +11,000	+200%	+$1.04M	0.79%	47
2023 Q1	$535K	Buy	+5,500	New	+$570K	0.37%	85
2021 Q4	$839K	Buy	9,500 +1,500	+19%	+$124K	0.24%	41
2021 Q3	$618K	Hold	8,000	–	–	0.16%	56
2021 Q2	$668K	Hold	8,000	–	–	0.18%	45
2021 Q1	$604K	Buy	8,000 +500	+7%	+$40.8K	0.2%	38
2020 Q4	$658K	Buy	7,500 +5,250	+233%	+$416K	0.27%	22
2020 Q3	$171K	Buy	+2,250	New	+$228K	0.08%	50

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

AlphaCentric Advisors's BMRN Position: Q4 2024 in Review

AlphaCentric Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 32,500 shares — an estimated $2.28M sold.

AlphaCentric Advisors first reported a position in BMRN in Q3 2020 and held it in 13 quarters. The position peaked at $2.28M in Q3 2024. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

AlphaCentric Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
AlphaCentric Advisors sold 32,500 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $2.28M.
AlphaCentric Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 13 quarters.
AlphaCentric Advisors's BioMarin Pharmaceuticals position peaked at $2.28M in Q3 2024.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.